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tiveness analyses were compared with methods specified by NICE as the reference 
case in its 2004 and 2008 Methods Guides. The review focused on guidance published 
before June 2013 for medicines treating metastatic breast cancer, metastatic colorectal 
cancer, metastatic hormone-refractory prostate cancer and metastatic non-small-
cell lung cancer. Nineteen technology appraisals published between March 2002 and 
August 2012 met the inclusion criteria. Results: Common themes or variations that 
exist between utility values selected by manufacturers and independent academic 
groups for each metastatic cancer and between the 4 metastatic cancers were ana-
lysed. The research also explored the methodological issues that were considered by 
the Appraisal Committee relating to the selection of utility values. ConClusions: 
Therefore, this research provides insight to the methodological considerations regard-
ing incorporation of utility values that have informed health technology assessment 
decision-making in England for 4 metastatic cancers.
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objeCtives: Patients with BM from solid tumors often experience skeletal-related 
events [SREs]; commonly defined as pathologic fracture, radiation or surgery to 
bone, and spinal cord compression. Several bone-targeted agents are approved for 
the prevention of SREs. This study evaluated US patients’ and caregivers’ prefer-
ences in relation to available treatment options in the US. Methods: Adults with 
or adult caregivers of patients with a self-reported physician diagnosis of BM from 
a solid tumor completed a web-enabled discrete-choice experiment survey com-
prising a series of 10 choices between pairs of hypothetical medication profiles. 
Each profile included 6 medication attributes within a pre-defined range (primarily 
based on prescribing information and real-world practice): months until first SRE 
(10, 18 and 28 months); months until worsening of pain (3, 6, 10 months); annual 
risk of osteonecrosis of the jaw (ONJ; 0%, 1%, 5%); annual risk of renal impairment 
(0%, 4%, 10%); mode of administration (subcutaneous injection, 15-minute infusion, 
120-minute infusion); and monthly out-of-pocket cost to patients ($25, $75, $150, 
$330). Choice questions were based on an experimental design with known statisti-
cal properties. The survey was pretested with 15 patients and 11 caregivers using 
open-ended interviews. A separate main-effects random parameters logit model 
was estimated. Results: In total, 187 patients and 197 caregivers completed the 
survey. Among the attribute levels included, out-of-pocket cost to patients, risk of 
renal impairment, and months until first SRE were most important to both patients 
and caregivers. For those attributes, better outcomes were preferred to worse out-
comes (p< 0.05) except that risk of renal impairment between 4% and 10% was not 
significant for patients; costs between $25 and $75 were not significant for either 
group. ConClusions: When considering treatment choices for preventing skeletal 
complications associated with BM, patients and caregivers focused mainly on out-
of-pocket cost to patients, avoiding renal impairment, and delaying SREs.
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objeCtives: In 2009, the FDA released Final Guidance on Patient-Reported 
Outcomes (PROs) and has stated that standards for PROs apply equally to Clinician 
and Observer Reported Outcomes (ClinROs, ObsROs; collectively, clinical out-
come assessments - COAs). The objective was to survey labels for oncologic drugs 
approved in the three years since the “PRO Guidance” was finalized and to charac-
terize any COAs in these labels. Methods: CenterWatch maintains a list of FDA 
approved drugs following definitions established by the Tufts Center for the Study 
of Drug Development, including only drugs or NMEs newly approved by the FDA 
Center for Drug Evaluation and Research. From 2010 to the time of this review in 
2013, 45 oncologic drugs were approved by the FDA. The FDA approved product 
labels of each of these drugs was reviewed and each was tabulated according to its 
inclusion of COAs. Results: Few of the approved product labels reviewed included 
any reference to, much less data collected using PROs, ClinROs, or ObsROs. Several 
(e.g., carfilzomib) had clear statements to indicate that approval for the product was 
based on a predefined response rate rather than any “improvement in survival or 
symptoms.” The notable exceptions are fentanyl sublingual tablets and spray and 
abiraterone, with PRO data on pain. ConClusions: There are several explanations 
for the low rate of COAs in oncology labels, especially that oncology trials tend to be 
unblinded. The FDA has stated that open label designs cannot support PRO claims. 
Yet there is still a heavy reliance on outcomes such as progression free and overall 
survival. Three labels were identified with PRO data on pain, two of which were spe-
cifically indicated for pain rather than tumor control. This review suggests there are 
opportunities for sponsors and the FDA to increase the degree to which the patient’s 
voice is heard during the regulatory decision making process.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for collecting 
and generating evidence for new medical products to show improvements in health-
related quality of life (HRQoL). Chronic myeloid leukemia (CML) is now a chronic 
disease in which HRQoL is becoming important. The objective of this study was to 
review, analyze, and understand trends in the PRO instruments used in patients with 
CML. Methods: A systematic literature search for CML randomized controlled tri-
als (RCTs) with PROs endpoints was undertaken for the databases Pubmed, Embase, 
Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interven-
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objeCtives: This study examined the responsiveness of preference-based meas-
ures based on the anchor of self-reported change in general health condition of 
patients with colorectal cancer (CRC). Methods: A baseline sample of 333 patients 
was recruited at the specialist outpatient clinic of academic teaching hospital in 
Hong Kong between September 2009 and July 2010, and was surveyed prospectively 
at 6-month follow-up. SF-6D preference-based indices were derived from the generic 
SF-6D measure (SF-6DDirect), from the Short Form-12 Health Survey (SF-6DSF-12) and 
also mapped from the condition-specific Functional Assessment of Cancer Therapy-
Colorectal (SF-6DFACT-C). The responsiveness of three measures was assessed using 
the internal responsiveness and external responsiveness. The 95% bias-corrected 
and accelerated bootstrapping confidence intervals were performed to compare the 
internal responsiveness statistics measured by standardized effect size, standard-
ized response mean, and responsiveness statistic. External responsiveness was 
evaluated by receiver operating characteristic (ROC) curve analysis that examined 
the ability to detect score changes with global health condition changes or dis-
criminate between the worsened and unchanged/improved groups. Results: 
Over half of patients reported no change in global health condition based on the 
self-reported anchor, whilst 15.1% and 32.9% of patients rated better and worse in 
current health condition compared to baseline respectively. In worsened group, 
internal responsiveness was satisfactory for the SF-6DDirect and SF-6DFACT-C prefer-
ence-based indices. The SF-6DSF-12 and SF-6DFACT-C indices were significantly more 
responsive to detect positive changes than the SF-6DDirect index in improved group. 
The SF-6DDirect and SF-6DFACT-C indices were more externally responsive based on 
ROC curve. The SF-6DFACT-C index was generally more responsive to changes in 
health status compared with other indices. ConClusions: Direct SF-6D measure 
was more responsive than mapped preference-based measures in improved group 
but the direction was reversed in worsened group. Use of a preference-based index 
mapped from a condition-specific measure captures both negative and positive 
important changes in HRQOL score among CRC.
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objeCtives: To elicit utility values from EQ-5D for patients with various stages of 
mCRC. Methods: An observational cross-sectional study consisting of one-time 
EQ-5D completion at enrollment was conducted in five hospitals in The Netherlands 
and the United Kingdom (UK). Patients were categorized into stable or progressed 
cohorts based on investigator assessment. Patients with mCRC were eligible if on 
second or subsequent lines of treatment or best supportive care [BSC], received 
prior oxaliplatin, no prior irinotecan, and had Eastern Cooperative Oncology Group 
(ECOG) performance status scores of 0-2 at second line initiation similar to the 
VELOUR trial. Chart data on patient demographics, clinical history, prior/current 
treatments, serious adverse events (SAEs) were collected. Average utilities were 
estimated; uni- and multivariate analyses were conducted. Results: A total of 
75 patients were enrolled, 42 patients stable on second line or third line follow-
ing an AE on second line and 33 progressed patients. Mean age was 63 (standard 
deviation [SD]= 10); 52% male. Most patients in the stable (98%) and progressed 
(88%) cohorts had ECOG scores of 0-1 at enrollment. 7% and 15% of patients in 
stable and progressed cohorts respectively had ongoing SAEs at enrollment. Mean 
utility scores were 0.741 (SD= 0.230) and 0.731 (SD= 0.292) for stable and progressed 
patients respectively. Higher proportions of patients reported increased anxiety/
depression (36% vs. 12%) and fewer problems with daily activities post-progression 
(64% vs. 38%). 83% and 42% of patients in stable and progressed cohorts respectively, 
were on treatment at enrollment. ConClusions: While the majority of the stable 
cohort had good performance status and few SAEs ongoing at enrollment, utility 
values were not much higher compared to the progressed cohort. Higher values in 
the progressed cohort may be attributed to exclusion of patients in palliative care 
centers, radiological versus symptomatic disease progression and patients remain-
ing on treatment, having few SAEs and good performance status at enrollment.
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objeCtives: National Institute for Health and Care Excellence (NICE) considers 
the quality-adjusted life year (QALY) to be the most appropriate generic measure of 
health benefit that reflects both mortality and health-related quality of life effects. 
The QALY is the sum of a person’s length of life in each health state multiplied by a 
quality-adjustment weight (that is, utility value) associated with that health state. 
Cost-effectiveness results are often sensitive to the choice of utility value, but relevant 
and comparable utility values are not always available leading to debate about the 
most appropriate utility values to include. The objective of the research was to review 
the health-related utility values used in economic models across NICE technology 
appraisal guidance for 4 metastatic cancers. Methods: A cross-sectional review of 
manufacturer submissions and reports produced by independent academic groups 
was carried out to identify the health-related utility values used. Information relating 
to the methods used to elicit utility values that were selected for use in cost-effec-
